SCOTUS denies Actavis' drug patent petition
The Supreme Court of the US (SCOTUS) has decided not to hear a patent case concerning whether a patent’s specification should
contain a written description of all of the limitations of a patent’s claims, not just a ‘substantially equivalent’ disclosure.
The rest of this document is only available to i-law.com online
If you are already a subscriber, please enter your details below to log in.